Cornerstone to take over marketing rights to Pertzye in US from Digestive Care
Pertzye, the pancreatic enzyme product, is indicated for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF). DCI earlier marketed the Pertzye formulation under
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.